Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy (RT-Immune)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03474094

Recruitment Status : Recruiting

First Posted : March 22, 2018

Last Update Posted : March 29, 2022

See Contacts and Locations

Sponsor:

Collaborator:

Roche Pharma AG

Information provided by (Responsible Party):

Centre Leon Berard

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Recruiting
Estimated Primary Completion Date :	August 1, 2022
Estimated Study Completion Date :	August 1, 2023

To Top